Recent events
Recent events tied to this brand in public sources.
Back to profile4 entries
2026
Celltrion unveils preclinical results for CT-G32/SCO-940
Celltrion unveiled preclinical findings for obesity drug candidate CT-G32/SCO-940, which the company said outperformed retatrutide in weight loss in tests involving obese rats and showed a smaller reduction in lean body mass relative to total weight loss. The candidate's safety and effectiveness in humans have not been established.
2022
South Korean regulator fines three Celltrion companies
South Korea's Financial Services Commission fined Celltrion, Celltrion Healthcare and Celltrion Pharm a combined 13 billion won for accounting-rule violations. The regulator concluded the violations were unintentional.
2020
Celltrion completes acquisition of Takeda primary care assets in Asia Pacific
Celltrion completed its acquisition of selected primary care assets from Takeda in Asia Pacific. Celltrion APAC assumed ownership of patent, trademark and sales rights for 18 products across nine markets.
2020
Celltrion agrees to acquire Takeda Asia Pacific product assets
Celltrion announced an agreement to acquire Takeda's Asia Pacific primary-care product assets, including rights for 18 products in nine markets, for USD 278.3 million. Completion was planned by the end of the fourth quarter, subject to regulatory approvals.